SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing a wave of bullish momentum fueled by speculative reports of Middle East diplomatic progress, triggering a significant short squeeze that has captured the attention of traders. The community remains deeply divided, with bulls aggressively targeting the $80,000 level and calling for a structural breakout, while vocal bears argue the asset is caught in a classic bear trap and remains structurally weak.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to a major policy catalyst following an executive order signed by President Trump, which aims to accelerate FDA breakthrough therapy reviews for psychedelic-based treatments like psilocybin and MDMA. The community is actively discussing the stock's potential re-rating and its position in the broader mental health innovation sector, with many focused on upcoming Phase 3 trial data as a primary catalyst for future valuation growth.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing significant community attention as investors debate its role as a core DeFi protocol amidst broader market volatility, with many highlighting its potential for long-term growth and its ability to act as a stable anchor compared to more speculative altcoins. Discussion is heavily focused on the stock's resilience, its status as a key infrastructure player, and the active accumulation strategies being employed by traders who view current price action as an opportunity to build long-term positions.

Highstreet

Highstreet is experiencing high trading volume and volatility, fueling intense community speculation about a potential short squeeze as participants debate its future against previous price levels. While some traders are aggressively adding to their positions in anticipation of a technical reversal, others are urging caution and highlighting the risks associated with the token's recent downward trend.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is currently trending as investors weigh the potential impact of a new executive order designed to fast-track FDA reviews for psychedelic-assisted therapies against ongoing volatility and concerns over clinical development timelines. The community is actively debating the company's long-term pipeline potential and leadership shifts, while some traders look for price momentum amid expectations for upcoming clinical data readouts.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending following a major executive order that prioritizes the fast-tracking of psychedelic therapies for mental health, fueling community anticipation for potential upcoming clinical trial readouts and regulatory shifts. Investors are actively discussing the stock's position as an industry leader and its pivotal role in the developing psychedelics sector amid broader policy tailwinds.

PolySwarm

PolySwarm is capturing investor attention as the community anticipates a long-awaited breakout, driven by its cybersecurity utility and low market cap. Discussion is currently dominated by bullish sentiment regarding the token's potential for explosive gains, whale accumulation patterns, and hopes for upcoming catalysts that could trigger a significant price reversal.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending due to anticipation surrounding the upcoming CHOPIN trial data, expected in mid-October, which investors hope will validate the platform's clinical value and potentially expand the Hepzato Kit's use as a frontline treatment. While recent revenue guidance and management's explanation of seasonal slowdowns caused significant volatility, the community remains divided, with bulls pointing to growing center activations, strong gross margins, and long-term pipeline potential in additional cancer indications as reasons to accumulate at lower price levels.

iShares Inc. - iShares MSCI Canada ETF

iShares MSCI Canada ETF

The iShares MSCI Canada ETF is currently a focal point in investor discussions due to heightened trade tensions between the US and Canada, as well as broader geopolitical concerns regarding North American supply chain autonomy. Market participants are actively debating the impact of tariff-related volatility on Canadian equities while analyzing how the country's commodity-heavy market is shifting its diplomatic and commercial ties toward China and other global partners.

iShares Trust - iShares 0-3 Month Treasury Bond ETF

iShares 0-3 Month Treasury Bond ETF

Investors are increasingly flocking to SGOV as a defensive parking spot to shelter capital from persistent market volatility and economic uncertainty. The community is actively discussing the ETF's role as a reliable, high-yield cash equivalent that offers stability and steady monthly distributions while they wait for better opportunities to re-enter the market.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The report, citing sources, said that the federal government is going to look closely at ibogaine’s safety and effectiveness.&nbsp;</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>The Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, the report added.</li></ul>Shares of Psyence Biomedical (PBM) more than doubled on Thursday following media reports that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.Shares of the company, which is advancing nature-derived psilocybin and ibogaine therapies, traded 141% higher at the time of writing, on track for its best session to date if gains hold.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs, based in Africa, as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Trump’s Upcoming Executive Order</h2>CBS News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a &nbsp;Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.An official told CBS News that medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's "snake oil" or a legitimate treatment.Other companies in the field of psychedelics, including Clearmind Medicine (CMND), AtaiBeckley (ATAI), GH Research (GHRS), and Compass Pathways (CMPS) are also trading higher on the news.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.A Stocktwits user noted that PBM stock is subject to “wild swings.”<stembedurl>https://www.stocktwits.com/dippin_stocks/message/650500248</stembedurl>Another user opined that the stock is going to be “highly volatile” but reach double digit.<stembedurl>https://www.stocktwits.com/momoneyinfla/message/650499935</stembedurl><a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has fallen by about 95% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM">ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.

Equity

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.


Compass Pathways (NASDAQ:CMPS) Sees Large Volume Increase - What's Next?

Compass Pathways (NASDAQ:CMPS) Sees Unusually-High Trading Volume - Still a Buy...

Short Interest in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Rises By 39.5%

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest...

Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness

Compass Pathways (NASDAQ:CMPS) executives outlined the company's latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami Fadia.

Phase 3 results highlighted rapid and durable antidepressant effects
CEO Kabir Nath said the...

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based...

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine analysts that are currently covering the company, Marketbeat Ratings...

Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the...

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees...

Compass Pathways PLC Sponsored ADR $CMPS Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 169.0% during the fourth quarter, according to the company in...

Compass Pathways (NASDAQ:CMPS) Given New $18.00 Price Target at Canaccord Genuity Group

Canaccord Genuity Group cut their price target on shares of Compass Pathways from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday...

CMPS
COMPASS Pathways

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CMPS News

CMPSCOMPASS Pathways